TABLE 1

Patient Characteristics and Treatment

Patient no.	Age (y)	Sex	Location	WHO grade	Before therapy	Octreotide uptake	Fractions/MBq	Karnofsky performance status	Response (RECIST)	PFS/OS (mo)
Treatment category 1^*
1	63	M	Falx bifrontal	II	S, RT	NA	2/1,688	80	PD	0/12
2	63	F	Skull base + parietal	I	S	2	3/4,500	90	SD	137+/137+
3	51	F	Convexity, multiple	III	S, RT, C	3	4/8,438	90	PD	4/22
4	56	F	Skull base	I	S	3	2/13,500	90	SD	87+/87+
5	44	M	Skull base	I	S, RT	3	2/14,800	90	SD	17/48+
6	46	F	Skull base	I	S	1	2/12,580	80	SD	24+/24+
7	47	F	Skull base	I	S	3	2/12,950	80	SD	72+/72+
8	67	M	Convexity, multiple	I	S, RT	2	2/13,320	60	SD	19/32
9	56	F	Skull base	I	S	2	2/11,840	100	SD	14+/14+
Treatment category 2^†
10	54	F	Skull base	II	—	2	2/13,320	90	SD	83+/83+
11	64	F	Skull base + temporal	NA	—	3	2/14,800	90	SD	68+/68+
12	43	F	Skull base	NA	—	2	2/13,690	90	SD	56+/56+
13	41	F	Pineal region	I	—	3	2/11,250	50	SD	57/57
14	71	F	Skull base + parietal	NA	—	3	2/12,210	80	SD	18/18
15	78	F	Skull base	I	S	1	2/13,320	70	SD	14/16

↵* Treatment after subtotal surgery and other pretreatment/diffuse tumor growth.
↵† Treatment due to severe medical comorbidity/refusal of surgical tumor resection.
Age = at initiation of ⁹⁰Y-DOTATOC; RECIST = Response Evaluation Criteria In Solid Tumors; S = surgery; RT = radiotherapy; NA = not applicable; PD = progressive disease; SD = stable disease; + = ongoing; multiple = ≥3 tumor locations; C = chemotherapy.